Previous 10 | Next 10 |
LAKE FOREST, Ill., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed its offering of $70 million aggregate principal amou...
Assertio ( NASDAQ: ASRT ) shares dropped ~26% pre-market on Tuesday after the specialty pharmaceutical company priced its private offering of $60M of 6.50% convertible senior notes due 2027 . The notes will will accrue interest at a rate of 6.50% per annum, payable semi-...
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the pricing of its offering of $60 million ...
Specialty pharmaceutical company Assertio Holdings ( NASDAQ: ASRT ) intends to offer $60M of convertible senior notes, due Sep. 1, 2027, to qualified institutional buyers. The offering is subject to market and other conditions. The company also plans to grant the initi...
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced its intention to offer, subject to market a...
Assertio Holdings has expanding sales and strong margins. ASRT is making moves to save money on debt servicing with strong cash on hand. The firm continues to raise guidance and be EPS positive. The valuation looks very attractive. Today we recommending a biotech/pha...
Assertio Holdings, Inc. (ASRT) Q2 2022 Earnings Conference Call August 08, 2022, 11:30 AM ET Company Participants Matthew Kreps - Darrow Associates, IR Daniel Peisert - President and CEO Paul Schwichtenberg - SVP and CFO Conference Call Participants S...
Shares of Assertio ( ASRT ) gained as much as 11.3% to $4.44 in Monday morning trading, after the specialty pharmaceutical company reported a Q2 profit compared to a loss a year ago and raised its FY 2022 guidance. ASRT stock had pared most of the gains and was last trading ...
Assertio Therapeutics press release ( NASDAQ: ASRT ): Q2 Non-GAAP EPS of $0.28. Revenue of $35.4M (+40.5% Y/Y). Gross profit margin in the second quarter was 87%. Raises 2022 financial guidance : Assertio increased its outlook for the full year 2022 r...
Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million Raises Full Year Revenue and Non-GAAP Adjusted EBITDA Guidance LAKE FOREST, Ill., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” ...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...